Evolution of СD95+-cells in peripheral blood of patients with ovarian cancer in during the combined treatment
https://doi.org/10.17650/1994-4098-2013-0-1-2-83-92
Abstract
Paper deals with the content of CD95+-cells in the blood of patients with ovarian cancer and benign tumors. Found that patients with a malignant process and low CD95+-cells before treatment and during chemotherapy have a poor survival. The initial increase in the relative level CD95+- cells has no effect on survival, increasing the relative level CD95+-cells during chemotherapy is associated with poor survival. Concluded that the CD95 can not be a factor in the forecast, but the reaction of the organism to maintain its level within the physiological range in the treatment of ovarian cancer patients can achieve significantly better long-term results.
About the Authors
N. G. Kormosh
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
T. N. Zabotina
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в Рос- сии и странах СНГ в 2007 г. Вестн РОНЦ 2009;20(3 прил 1):1–158.
2. http://seer.cancer.gov/csr/1975_2006/ browse_csr.php?section=21&page=sect_21_ table.08.html.
3. Strasser A., Jost P.J., Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009;30(2):180–92.
4. Reed J., Hakam A., Nicosia S.V., Coppola D. Significance of Fas receptor protein expression in epithelial ovarian cancer. Hum Pathol 2005;36(9):971–6.
5. Seki N., Brooks A.D., Carter C.R. et al. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand- mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
6. J Immunol 2002;168(7):3484–92.
7. Minas V., Rolaki A., Kalantaridou S.N. et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer 2007;97(5):637–45.
8. Duiker E.W., van der Zee A.G., de Graeff P. et al. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Gynecol Oncol 2010;116(3):549–55.
9. Антонеева И.И. Обоснование и совершенст- вование диагностики прогрессирующего рака яичников. Дис. ... д-ра мед. наук. Уфа, 2009.
10. Peter M.E., Budd R.C., Desbarats J. et al. The CD95 receptor: apoptosis revisited. Cell 2007;129(3):447–50.
11. Chen L., Park S.M., Tumanov A.V. et al. CD95 promotes tumour growth. Nature 2010;465(7297):492–6.
Review
For citations:
Kormosh N.G., Zabotina T.N. Evolution of СD95+-cells in peripheral blood of patients with ovarian cancer in during the combined treatment. Tumors of female reproductive system. 2013;(1-2):83-92. (In Russ.) https://doi.org/10.17650/1994-4098-2013-0-1-2-83-92
Views:
462
Email this article 